The Optic Neuritis Treatment Trial previously reported that corticosteroids accelerated visual recovery in optic neuritis (ON) without improving outcome. This finding related largely to multiple sclerosis (MS), and subsequently neurologists tended to await spontaneous recovery in ON. Since then, non-MS cases of ON have been identified with antibodies to aquaporin-4 (AQP4) or myelin oligodendrocyte glycoprotein (MOG). These disorders can closely mimic multiple sclerosis-associated or idiopathic demyelinating optic neuritis (MS/IDON) initially but risk a worse visual outcome. Scrutinising the clinical features and neuroimaging often enables differentiation between MS/IDON and other causes of ON. Early treatment with high-dose corticosteroids is an important determinant of visual outcome in non-MS/IDON. Prompt use of plasma exchange may also save sight. In this review, we contrast the presentations of myelin oligodendrocyte glycoprotein associated optic neuritis (MOG-ON) and aquaporin 4 associated optic neuritis (AQP4-ON) with MS/IDON and provide an approach to acute management while awaiting results of antibody testing.
- CLINICAL NEUROLOGY
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Contributors SC, VJMB and GTP formulated the idea for the article. All authors contributed significantly to the content of the manuscript, reviewed the drafts and provided feedback.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Commissioned; externally peer reviewed by Ed Margolin, Toronto, Canada, Christian Lueck, Canberra, Australia, and Jacqueline Palace, Oxford, UK.
Read the full text or download the PDF:
Other content recommended for you
- Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations
- Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease
- Myelin oligodendrocyte glycoprotein (MOG) antibody-associated longitudinally extensive transverse myelitis (LETM) and primary Sjogren syndrome: a rare association
- Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS
- Distinct clinical characteristics of atypical optic neuritis with seronegative aquaporin-4 antibody among Chinese patients
- Antibodies to myelin oligodendrocyte glycoprotein in chronic relapsing inflammatory optic neuropathy
- Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis
- Paediatric optic neuritis: factors leading to unfavourable outcome and relapses
- Recurrent visual loss in a 64-year-old man
- A practical approach to the diagnosis of spinal cord lesions